TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22844002

Group type: EXPERIMENTAL
Intervention: High-risk human papillomavirus (hrHPV) testing combined with cervical cytology
Number of subjects: 598

Group type: COMPARATOR
Intervention: Control group (hrHPV-negative women)
Number of subjects: 598

Group type: COMPARATOR
Intervention: hrHPV-negative women with normal or ASCUS cytological findings
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: If hrHPV-negative women had not been referred to colposcopy
Number of subjects: 598
Study: 20357149

Group type: EXPERIMENTAL
Intervention: Airway Scope (AWS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Airtraq (ATQ)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (ML)
Number of subjects: 24
Study: 18315966

Group type: EXPERIMENTAL
Intervention: Percutaneous treatment of displaced intra-articular calcaneal fractures
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control foot (contralateral foot)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Heel time ratio
Number of subjects: 21
Study: 15951651

Group type: EXPERIMENTAL
Intervention: Local corticosteroid injection
Number of subjects: 164

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 14634366

Group type: EXPERIMENTAL
Intervention: Portable device providing extrinsic auditory feedback in gait therapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional gait therapy only
Number of subjects: 16
Study: 10450289

Group type: EXPERIMENTAL
Intervention: DASH dietary pattern
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other dietary patterns
Number of subjects: 0
Study: 8678934

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 1746296

Group type: EXPERIMENTAL
Intervention: Diet and exercise followed by gemfibrozil therapy
Number of subjects: 3328
Study: 6280794

Group type: EXPERIMENTAL
Intervention: High dose cyclophosphamide alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus methotrexate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus methotrexate plus vincristine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus high‐dose methotrexate plus vincristine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic brain radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MACC (methotrexate, adriamycin, cyclophosphamide, CCNU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CCV/AV (cyclophosphamide, CCNU, vincristine, alternating with adriamycin and vincristine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Split course radiotherapy (total 45 Gy over 4 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic brain irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy to the chest
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 0
Study: 30724405

Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation (CR)
Number of subjects: 475

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 475
Study: 29177407

Group type: EXPERIMENTAL
Intervention: Extra early standard dose of measles vaccine (MV) (Edmonston‐Zagreb strain)
Number of subjects: 8309

Group type: COMPARATOR
Intervention: Control group (no extra MV)
Number of subjects: 8309
Study: 26586780

Group type: EXPERIMENTAL
Intervention: Continued thienopyridine
Number of subjects: 11648

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11648
Study: 23644703

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo (5% aqueous dextrose solution)
Number of subjects: 254
Study: 22529160

Group type: EXPERIMENTAL
Intervention: Structured home-based program (S-pre, n = 31)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Unstructured home-based program (U-free, n = 14)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy participants (n = 15)
Number of subjects: 60
Study: 20176670

Group type: EXPERIMENTAL
Intervention: Telephonic interpretation
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: In-person interpretation
Number of subjects: 1201

Group type: COMPARATOR
Intervention: Bilingual physician
Number of subjects: 1201
Study: 17377800

Group type: EXPERIMENTAL
Intervention: Fentanyl iontophoretic transdermal system (ITS)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Morphine intravenous patient‐controlled analgesia (IV PCA)
Number of subjects: 275
Study: 15705921

Group type: COMPARATOR
Intervention: LT4 monotherapy (n = 48)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: LT4/LT3, ratio 10:1 (n = 46)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: LT4/LT3, ratio 5:1 (n = 47)
Number of subjects: 141
Study: 12730320

Group type: EXPERIMENTAL
Intervention: Model predicting 12-month mortality based on age, gender, ADL difficulty, medical conditions, prior year hospitalizations, and primary caregiver relationship
Number of subjects: 3858

Group type: EXPERIMENTAL
Intervention: Model predicting mortality based on two or more activities of daily living (ADLs) difficulty
Number of subjects: 3858

Group type: EXPERIMENTAL
Intervention: Validation test of the prediction model
Number of subjects: 3858
Study: 12198786

Group type: EXPERIMENTAL
Intervention: Memory for responses to the softest and loudest stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Memory for responses to intermediate stimulus amplitudes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Memory for the range of stimulus amplitudes
Number of subjects: 0
Study: 8748357

Group type: EXPERIMENTAL
Intervention: Tube feeding (TF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (maintenance i.v. fluid)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 1940094

Group type: EXPERIMENTAL
Intervention: Imipramine (25 mg/daily)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 6117576

Group type: EXPERIMENTAL
Intervention: Nabilone (4 or 5 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nabilone (1 or 2 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nabilone (lower doses)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31138184

Group type: EXPERIMENTAL
Intervention: Norethindrone 5 mg three times daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Combined oral contraceptives (OCP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Norethindrone
Number of subjects: 50
Study: 27743908

Group type: EXPERIMENTAL
Intervention: Parent-based cognitive behavioral therapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Parent-based psychoeducation
Number of subjects: 52
Study: 25635606

Group type: EXPERIMENTAL
Intervention: Combined group (plyometric + acceleration + dribbling + shooting)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (soccer training only)
Number of subjects: 26
Study: 25012423

Group type: EXPERIMENTAL
Intervention: Group support psychotherapeutic intervention
Number of subjects: 77

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 77
Study: 21136310

Group type: EXPERIMENTAL
Intervention: Postconditioning
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard of care (Control)
Number of subjects: 43
Study: 19349122

Group type: EXPERIMENTAL
Intervention: Hybrid cognitive-behavioral therapy (H-CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 17967760

Group type: EXPERIMENTAL
Intervention: Diet 3 (40% carbohydrate, 30% fat, 25% protein)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Diet 4 (40% carbohydrate, 30% fat, 25% protein and caloric restriction)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Diet 1 (55% carbohydrate, 30% fat, 15% protein)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Diet 2 (55% carbohydrate, 30% fat, 15% protein and caloric restriction)
Number of subjects: 94
Study: 15534251

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (5 g per day)
Number of subjects: 104
Study: 15649161

Group type: EXPERIMENTAL
Intervention: Laser acupuncture on P6 point and saline infusion
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.1 mg.kg(‐1) i.v. and sham laser
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham laser and saline infusion
Number of subjects: 120
Study: 10578981

Group type: EXPERIMENTAL
Intervention: Sialosyl-Tn (STn) monoclonal antibody staining
Number of subjects: 72
Study: 9081852

Group type: EXPERIMENTAL
Intervention: 1.25 mg ramipril daily
Number of subjects: 619

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 619
Study: 1847026

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (15,000 UaXa, subcutaneous, daily for 6 months)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (subcutaneous, daily for 6 months)
Number of subjects: 44
Study: 6340974

Group type: EXPERIMENTAL
Intervention: Trimethoprim (250 mg)/sulfamethopyrazine (200 mg) combination given once daily after a double loading dose on the first day.
Number of subjects: 68

Group type: COMPARATOR
Intervention: Ampicillin 500 mg 4-times daily.
Number of subjects: 68
Study: 31655882

Group type: EXPERIMENTAL
Intervention: Glove-finger pack soaked with saline solution
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lidocaine-soaked pack
Number of subjects: 120
Study: 30667512

Group type: EXPERIMENTAL
Intervention: Standard radial extracorporeal shock wave device
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Standard radial extracorporeal shock wave device modified to give a more sophisticated appearance
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Standard radial extracorporeal shock wave device modified to give a more austere appearance
Number of subjects: 135
Study: 27377131

Group type: EXPERIMENTAL
Intervention: iPad applications targeting VMI skills
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional occupational therapy intervention sessions targeting VMI skills
Number of subjects: 20
Study: 26290524

Group type: EXPERIMENTAL
Intervention: In-home caregiver-mediated module
Number of subjects: 147

Group type: COMPARATOR
Intervention: Group-based caregiver education module
Number of subjects: 147
Study: 24830400

Group type: EXPERIMENTAL
Intervention: Prophylactic clip
Number of subjects: 195

Group type: COMPARATOR
Intervention: Endoloop
Number of subjects: 195
Study: 22811376

Group type: EXPERIMENTAL
Intervention: MVit (VitC: 200 mg; VitE: 400 IU; VitB6: 25 mg; Folic Acid: 400 ug; VitB12: 400 ug)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MVit + N3 (2 g N3, 760 mg EPA, 440 mg DHA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MVit
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MVit + N3
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: N3 (2 g N3, 760 mg EPA, 440 mg DHA)
Number of subjects: 100
Study: 19056661

Group type: EXPERIMENTAL
Intervention: Garlic supplementation (aged garlic and steam-distilled garlic oil) for 7.3 years
Number of subjects: 3411

Group type: EXPERIMENTAL
Intervention: Vitamin and selenium supplementation for 7.3 years
Number of subjects: 3411

Group type: COMPARATOR
Intervention: Anti-H. pylori treatment with amoxicillin (1 g twice daily) and omeprazole (20 mg twice daily)
Number of subjects: 3411

Group type: COMPARATOR
Intervention: Vitamin B-12 and homocysteine levels
Number of subjects: 3411
Study: 17908276

Group type: EXPERIMENTAL
Intervention: Concentration-controlled MMF dosing
Number of subjects: 137

Group type: COMPARATOR
Intervention: Fixed-dose MMF
Number of subjects: 137
Study: 15036828

Group type: EXPERIMENTAL
Intervention: Presence of 1 component of metabolic syndrome
Number of subjects: 6182

Group type: EXPERIMENTAL
Intervention: Presence of 2 components of metabolic syndrome
Number of subjects: 6182

Group type: EXPERIMENTAL
Intervention: Presence of 3 components of metabolic syndrome
Number of subjects: 6182

Group type: EXPERIMENTAL
Intervention: Presence of 4 or more components of metabolic syndrome
Number of subjects: 6182
Study: 11751658

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL 12.5 mg once daily
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL titrated to 200 mg once daily
Number of subjects: 14
Study: 9428538

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at 5 ppm
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo (nitrogen gas)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 177
Study: 8116033

Group type: EXPERIMENTAL
Intervention: Standard intravenous immunoglobulin (IVIG; 0.5 g/kg) for 6 doses and oral acyclovir for 3 months
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir (2.5 mg/kg) twice daily for 2 weeks followed by oral acyclovir for 3 months
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Cytogam (100-150 mg/kg) plus 2 weeks of i.v. ganciclovir followed by 3 months of oral acyclovir
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard IVIG (5 doses over 2 months)
Number of subjects: 82
Study: 30286025

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy for patients with locally advanced disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective use of radiation in the context of the PROSPECT randomized controlled trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonoperative management in the context of the Organ Preservation in Rectal Adenocarcinoma trial
Number of subjects: 0
Study: 28586510

Group type: EXPERIMENTAL
Intervention: 10‐s maximum‐effort sprint
Number of subjects: 9

Group type: COMPARATOR
Intervention: 10‐s rest
Number of subjects: 9
Study: 26202994

Group type: EXPERIMENTAL
Intervention: 2% Articaine (A2)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 4% Articaine (A4)
Number of subjects: 46
Study: 24261013

Group type: EXPERIMENTAL
Intervention: Sport education classes
Number of subjects: 6

Group type: COMPARATOR
Intervention: Traditional teacher-directed format
Number of subjects: 6
Study: 21979399

Group type: EXPERIMENTAL
Intervention: Diabetic colon preparation (10 ounces of magnesium citrate 2 days prior, followed by 10 ounces of magnesium citrate and 4-L polyethylene glycol the day prior)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Standard colon preparation (10 ounces of magnesium citrate and 4-L polyethylene glycol the day prior)
Number of subjects: 198
Study: 19819612

Group type: EXPERIMENTAL
Intervention: Doorstep canvassing by trained canvassers
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control group (no canvassing)
Number of subjects: 194
Study: 16822111

Group type: EXPERIMENTAL
Intervention: 8-session intervention focusing on Internet information consumer skills
Number of subjects: 448

Group type: COMPARATOR
Intervention: Time-matched support group
Number of subjects: 448
Study: 12587892

Group type: EXPERIMENTAL
Intervention: Bungy squat jumps
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-bungy squat jumps
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 10918990

Group type: EXPERIMENTAL
Intervention: Moderate whey hydrolysate formula (pHF, Nestlé Beba HA) and breastfeeding, with no weaning food before 4 months of age (Z cohort, n = 564)
Number of subjects: 1130

Group type: COMPARATOR
Intervention: No intervention (FF cohort, n = 566)
Number of subjects: 1130
Study: 9051332

Group type: EXPERIMENTAL
Intervention: SMS 201‐995 (100 micrograms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0
Study: 8266005

Group type: EXPERIMENTAL
Intervention: Water immersion
Number of subjects: 18
Study: 3488385

Group type: EXPERIMENTAL
Intervention: Erythromycin ethyl succinate
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 30092768

Group type: EXPERIMENTAL
Intervention: Educational leaflet explaining symptoms of gynaecological cancers
Number of subjects: 15538

Group type: COMPARATOR
Intervention: Control group (no leaflet)
Number of subjects: 15538
Study: 27813503

Group type: EXPERIMENTAL
Intervention: Naproxen sodium, paracetamol and pamabrom
Number of subjects: 189

Group type: COMPARATOR
Intervention: Paracetamol, pyrilamine and pamabrom
Number of subjects: 189
Study: 23633128

Group type: EXPERIMENTAL
Intervention: D-mannose powder (2 g in 200 ml of water daily for 6 months)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin (50 mg daily)
Number of subjects: 308

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 308
Study: 22581047

Group type: EXPERIMENTAL
Intervention: Temporal phacoemulsification
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Temporal SICS
Number of subjects: 405
Study: 20034729

Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 957

Group type: COMPARATOR
Intervention: Epirubicin
Number of subjects: 957
Study: 18619113

Group type: EXPERIMENTAL
Intervention: Nitrogen narcosis
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Alcohol (0.5 g/kg dose)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 62
Study: 15984978

Group type: EXPERIMENTAL
Intervention: VSL#3, 3,600 billion bacteria daily in two divided doses for 6 weeks
Number of subjects: 34
Study: 12461219

Group type: EXPERIMENTAL
Intervention: Intensive case management
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard case management
Number of subjects: 146
Study: 10515442

Group type: EXPERIMENTAL
Intervention: Imidapril for 12 weeks (Period I)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Enalapril for 12 weeks (Period I)
Number of subjects: 489
Study: 8821078

Group type: EXPERIMENTAL
Intervention: L-Dopa medication
Number of subjects: 12

Group type: COMPARATOR
Intervention: Withdrawal of L-Dopa
Number of subjects: 12
Study: 2026989

Group type: EXPERIMENTAL
Intervention: Genuine acupuncture
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 33
Study: 7294616

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (Healon) used during IOL implantation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional IOL implantation (Control)
Number of subjects: 20
Study: 31454432

Group type: EXPERIMENTAL
Intervention: Primary debulking surgery (PDS)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy with interval debulking
Number of subjects: 101
Study: 29471922

Group type: EXPERIMENTAL
Intervention: Approach bias modification (ApBM)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham-Approach bias modification (sham-ApBM)
Number of subjects: 33
Study: 26906704

Group type: EXPERIMENTAL
Intervention: Domestic made aspheric intraocular lens (Model: A1-UV)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Imported aspheric intraocular lens (Model: SN60WF)
Number of subjects: 119
Study: 24490769

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafts (CABG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 0

Group type: COMPARATOR
Intervention: First generation drug-eluting stents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Latest generation drug-eluting stents
Number of subjects: 0
Study: 22904010

Group type: EXPERIMENTAL
Intervention: Biomechanical evidence presented at sentencing
Number of subjects: 181

Group type: COMPARATOR
Intervention: Hypothetical case without biomechanical evidence
Number of subjects: 181
Study: 20451404

Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) 75 mg/m² subcutaneously for 7 days every 28 days (n=38)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Conventional care regimens (CCR) (n=49)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Conventional care regimens (CCR)
Number of subjects: 87
Study: 17548850

Group type: EXPERIMENTAL
Intervention: Home visiting program
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 84
Study: 16103896

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 2735

Group type: COMPARATOR
Intervention: Fluvastatin, Lovastatin, Pravastatin, Simvastatin
Number of subjects: 2735
Study: 12370520

Group type: EXPERIMENTAL
Intervention: NNRTI-containing regimens initiated in patients with hypersusceptibility (n = 21)
Number of subjects: 177

Group type: COMPARATOR
Intervention: NNRTI-containing regimens initiated in patients without hypersusceptibility (n = 77)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Patients with hypersusceptible virus
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Hypersusceptibility to NNRTI
Number of subjects: 177
Study: 10193975

Group type: EXPERIMENTAL
Intervention: Famciclovir 500 mg twice daily
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Famciclovir 250 mg twice daily
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (patients with a positive history of oral herpes labialis)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (patients without a known HSV history)
Number of subjects: 99
Study: 7572006

Group type: EXPERIMENTAL
Intervention: Desmopressin (0.3 microgram/kg body weight)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 2271467

Group type: EXPERIMENTAL
Intervention: Group 1 (subclavian perivascular injection after withdrawing from the artery)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Group 2 (subclavian perivascular injection after advancing through the artery)
Number of subjects: 18
Study: 7270401

Group type: EXPERIMENTAL
Intervention: Intravenous prenalterol (PNL) 75 to 225 microgram/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intravenous prenalterol (PNL) during exercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oral prenalterol (PNL) 30 to 200 mg/day
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oral prenalterol (PNL) vs placebo
Number of subjects: 8
Study: 31764465

Group type: EXPERIMENTAL
Intervention: WALK3 (30-min sitting/3-min brisk treadmill walk)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: WALK5 (45-min sitting/5-min brisk treadmill walk)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: WALK8 (60-min sitting/8-min brisk treadmill walk)
Number of subjects: 16

Group type: COMPARATOR
Intervention: SIT (9-h uninterrupted sitting)
Number of subjects: 16
Study: 30348198

Group type: EXPERIMENTAL
Intervention: Treadmill gait training plus visual feedback (+VFB)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Treadmill walking without visual feedback (Control)
Number of subjects: 48